Back to top
more

Seattle Genetics, Inc. (SGEN)

(Delayed Data from NSDQ)

$67.25 USD

67.25
574,388

+0.33 (0.49%)

Updated May 3, 2019 04:00 PM ET

After-Market: $67.27 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Company News For Oct 1, 2019

Companies In The News Are: BX,THO,SGEN,XEL

Seattle Genetics' Enfortumab Vedotin BLA Gets Priority Review

The FDA accepts Seattle Genetics (SGEN) and Astellas' BLA for enfortumab vedotin under a priority review to treat advanced/metastatic urothelial cancer. A verdict is pending on Mar 15, 2020.

Why Is Seattle Genetics (SGEN) Up 2.4% Since Last Earnings Report?

Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Seattle Genetics (SGEN) Q2 Loss Narrows, Sales Top Estimates

Seattle Genetics (SGEN) betters loss estimates and rides high on revenue beat in Q2.

Seattle Genetics (SGEN) Reports Q2 Loss, Tops Revenue Estimates

Seattle Genetics (SGEN) delivered earnings and revenue surprises of 38.46% and 14.25%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Seattle Genetics (SGEN) Q2 Earnings Expected to Decline

Seattle Genetics (SGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Roche's Rozlytrek Gets Approval in Japan for Solid Tumors

Roche's (RHHBY) oncology portfolio gets a boost with the approval of Rozlytrek for neurotrophic tyrosine receptor kinase fusion-positive, advanced recurrent solid tumors.

Roche's Polivy Gets FDA Nod, Gazyva Meets Goals in Phase II

Roche's (RHHBY) hematology portfolio gets a boost as FDA approves Polivy for DLBCL, and lymphoma drug, Gazyva, meets goals in a phase II study.

Seattle Genetics, Astellas' Cancer Candidate Attains 44% ORR

Seattle Genetics (SGEN) and Astellas post favorable data from the first cohort of a phase II study on enfortumab vedotin for treating advanced/metastatic urothelial cancer. Shares up as the candidate achieves 44% ORR.

Seattle Genetics (SGEN) Down 2.7% Since Last Earnings Report: Can It Rebound?

Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Seattle Genetics (SGEN) Q1 Loss Narrows, Revenues Top Mark

Seattle Genetics (SGEN) betters loss estimates in Q1 and also rides high on revenue beat.

Will Seattle Genetics (SGEN) Report Negative Earnings Next Week? What You Should Know

Seattle Genetics (SGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seattle Genetics' Adcetris Progresses Well Amid Competition

Seattle Genetics (SEGN) focuses on improving sales of its flagship product, Adcetris. The drug's label expansion programs also appear encouraging.

Seattle Genetics (SGEN) Surges: Stock Moves 7.6% Higher

Seattle Genetics (SGEN) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Seattle Genetics Closes Enrollment in Cervical Cancer Study

Seattle Genetics (SGEN) and partner Genmab end enrollment in the phase II study on tisotumab vedotin for treating patients with advanced/metastatic cervical cancer.

Seattle Genetics, Astellas Report Positive Cancer Study Data

Seattle Genetics (SGEN) and partner Astellas present positive top-line data from the first cohort of a phase II study on enfortumab vedotin for treating patients with advanced/metastatic urothelial cancer.

Seattle Genetics (SGEN) Down 6.1% Since Last Earnings Report: Can It Rebound?

Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Biotech Stock Roundup: Regeneron Impresses in Q4, Gilead Slumps, MacroGenics Soars

Key highlights of the week were fourth-quarter results from Regeneron Pharmaceuticals and Ligand Pharmaceuticals along with other regulatory and pipeline updates.

Seattle Genetics' Adcetris Gets EC Nod for Label Expansion

Seattle Genetics' (SGEN) partner, Takeda Pharmaceutical receives EC approval for Adcetris in combination with AVD to treat adults with previously untreated CD30+ stage IV cHL.

Seattle Genetics (SGEN) Q4 Loss Widens, Revenues Top Mark

Seattle Genetics (SGEN) incurs wider-than-expected loss in Q4 but rides high on revenue beat.

Seattle Genetics (SGEN) Reports Q4 Loss, Tops Revenue Estimates

Seattle Genetics (SGEN) delivered earnings and revenue surprises of -46.15% and 5.26%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

What's in the Cards for Glaxo (GSK) This Earnings Season?

Glaxo's (GSK) Vaccines segment is likely to witness strong sales in the fourth quarter.

Regeneron (REGN) to Report Q4 Earnings: Is a Beat in Store?

Strong Eylea and Dupixent sales are likely to propel better-than-expected results for Regeneron (REGN) when it reports fourth-quarter results.

Seattle Genetics (SGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Seattle Genetics (SGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seattle Genetics (SGEN) Looks Good: Stock Adds 5.6% in Session

Seattle Genetics (SGEN) saw a big move last session, as its shares jumped nearly 6% on Friday, amid huge volumes.